Outcomes for schizophrenia patients with clozapine treatment: How good does it get?

Journal of Psychopharmacology

Volumn 23, Issue 8, 2009, Pages 957-965

  Wheeler, A ^a,b   Humberstone, V ^c   Robinson, G ^d  

^a Waitakere Hospital   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Manukau SuperClinic   (New Zealand)

^d WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Audit; Clozapine; Outcome; Schizophrenia

Indexed keywords

CLOZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FUNCTIONAL ASSESSMENT; HEALTH SERVICE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; MENTAL PATIENT; OCCUPATION; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SOCIAL ASPECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CROSS-SECTIONAL STUDIES; HUMANS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 70449356886     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108093588     Document Type: Article

References (42)

1. American Psychiatric Association (2004) Practice Guideline for the Treatment of Patients With Schizophrenia. Washington, DC: Second American Psychiatric Association.
2. Atkinson, JM, Douglas-Hall, P., Fischetti, C., Sparshatt, A., Taylor, DM (2007) Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry 68: 1027-1030.
3. Bailey, D. (1992) A Users Guide to the Mental Health (Compulsory Assessment and Treatment) Act. Wellington: Department of Health.
4. Carr, VJ, Neil, AL, Halpin, SA, Holmes, S., Lewin, TJ (2003) Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 37: 31-40.
5. Ciapparelli, A., DellOsso, L., Bandettini di Poggio, A., Carmassi, C., Cecconi, D., Fenzi, M., et al. (2003) Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 64: 451-458.
6. Citrome, L., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, JP, McEvoy, J., et al. (2001) Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 52: 1510-1514.
7. Conley, RR, Buchanan, RW (1997) Evaluation of treatment-resistant schizophrenia. Schizophr Bull 23: 663-674.
8. Conley, RR, Kelly, DL, Lambert, TJ, Love, RC (2005) Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr Serv 56: 320-323.
9. Davies, LM, Drummond, MF (1994) Economics and schizophrenia: the real cost. Br J Psychiatry Suppl 25: 18-21.
10. Duggan, A., Warner, J., Knapp, M., Kerwin, R. (2003) Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 182: 505-508.
11. Gureje, O., Herrman, H., Harvey, C., Morgan, V., Jablensky, A. (2002) The Australian National Survey of Psychotic Disorders: profile of psychosocial disability and its risk factors. Psychol Med 32: 639-647.
12. Henderson, DC, Nguyen, DD, Copeland, PM, Hayden, DL, Borba, CP, Louie, PM, et al. (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 66: 1116-1121.
13. Hennen, J., Baldessarini, RJ (2005) Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 73: 139-145.
14. Humberstone, V., Wheeler, A., Lambert, T. (2004) An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry 38: 240-245.
15. Jablensky, A., McGrath, J., Herrman, H., Castle, D., Gureje, O., Evans, M., et al. (2000) Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust N Z J Psychiatry 34: 221-236.
16. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796.
17. Killian, JG, Kerr, K., Lawrence, C., Celermajer, DS (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet 354: 1841-1845.
18. Krakowski, MI, Czobor, P., Citrome, L., Bark, N., Cooper, TB (2006) Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 63: 622-629.
19. La Grenade, L., Graham, D., Trontell, A. (2001) Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 345: 224-225.
20. Leslie, DL, Rosenheck, R. (2002) Third Annual Report on Pharmacotherapy of Schizophrenia in the Department of Veterans Affairs. West Haven, CT: Northeast Program Evaluation Centre.
21. Lewis, SW, Barnes, TRE, Davies, L., Murray, RM, Dunn, G., Hayhurst, KP, et al. (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32: 715-723.
22. Libbus, Y., Gardner, D., Milliken, H. (2006) Utilization of Clozapine in Nova Scotia 1990-2004. Canadian Psychiatric Association 56th Annual Conference. Toronto, Canada: Canadian Psychiatric Association.
23. Lindstrom, LH (1994) Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand 89: 74-76. Littrell, K. (1995) Maximizing schizophrenia treatment outcomes: a model for reintegration. Psychiatr Rehabil J 19: 75.
24. Magnus, A., Carr, V., Mihalopoulos, C., Carter, R., Vos, T. (2005) Assessing cost-effectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry 39: 44-54.
25. McEvoy, JP, Lieberman, JA, Stroup, TS, Davis, SM, Meltzer, HY, Rosenheck, RA, et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600-610.
26. Meltzer, HY, Bastani, B., Kwon, KY, Ramirez, LF, Burnett, S., Sharpe, J. (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 99 (Suppl. 1). S68 - S72.
27. Meltzer, HY, Burnett, S., Bastani, B., Ramirez, LF (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenia patients. Hosp Community Psychiatry 41: 892-897.
28. Meltzer, HY, Cola, P., Way, L., Thompson, PA, Bastani, B., Davies, MA, et al. (1993) Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 150: 1630-1638.
29. Ministry of Health (1997) National Acuity Review: Final Report on New Zealands Mental Health Acute Inpatient Services. Wellington: Ministry of Health.
30. Morris, S., Hogan, T., McGuire, A. (1998) The cost-effectiveness of clozapine: a survey of the literature. Clin Drug Investig 15: 137-152.
31. New Zealand Guidelines Group (2003) The assessment and management of cardiovascular risk. In (Nzgg) (ed).
32. New Zealand Mental Health Metabolic Working Group (2006) A New Zealand Mental Health Metabolic Working Group Initiative. Auckland: Janssen Cilag Ltd.
33. Nice (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: National Institute for Clinical Evidence.
34. Reid, WH, Mason, M. (1998) Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. J Clin Psychiatry 59: 189-194.
35. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Schizophrenia and Related Disorders (2005) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 39: 1-30.
36. Safferman, A., Lieberman, JA, Kane, JM, Szymanski, S., Kinon, B. (1991) Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17: 247-261.
37. Sernyak, MJ, Rosenheck, R., Desai, R., Stolar, M., Ripper, G. (2001) Impact of clozapine prescription on inpatient resource utilization. J Nerv Ment Dis 189: 766-773.
38. Thornicroft, G., Tansella, M., Becker, T., Knapp, M., Leese, M., Schene, A., et al. (2004) The personal impact of schizophrenia in Europe. Schizophr Res 69: 125-132.
39. Tiihonen, J., Walhbeck, K., Lonnqvist, J., Klaukka, T., Ioannidis, JPA, Volavka, J., et al. (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333: 224.
40. Wahlbeck, K., Cheine, M., Essali, MA (2000) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2: CD000059.
41. Weissman, EM (2002) Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region. Schizophr Bull 28: 31-42.
42. Wheeler, A. (2007) Sociodemographic, functional and clinical correlates in outpatients with schizophrenia: comparison with affective disorders. Aust N Z J Psychiatry 41: 809-818.